Navigation Links
Acrongenomics Acquires Equity Stake in Molecular Vision
Date:2/4/2008

focused on applying its technology to the medical diagnostics markets.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

For more informat
'/>"/>

SOURCE Acrongenomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Neogen Acquires Kane Enterprises
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
5. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
6. NSF International Acquires David Begg Associates
7. United BioSource Acquires Caro Research, Leader in Simulation Modeling
8. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
9. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Thermo Fisher Scientific Acquires Leader in Micro-Volume Spectrophotometers, NanoDrop Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... , an English-language journal jointly published by Springer and Tsinghua ... (SCI-E). The academic journal, founded in July 2008, has ... Nano Research is part of Springer,s Chinese Library ... Nano Research is an international, interdisciplinary journal which ...
(Date:3/17/2010)... Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms ... results for the third  fiscal quarter ended January 31, 2010 .  Full details of ... ... ...
(Date:3/17/2010)... March 17 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the ... its fourth quarter and full year 2009 financial and operating results before market ... conference call and webcast to discuss these results later that same day at ... ...
(Date:3/17/2010)... Carl ... , ... March 17, 2010 -- Carl Zeiss, a leading provider of microscopy solutions ... promotions. For a limited time, and only available online, these special web promotions include ...
Breaking Biology Technology:China's first open-access journal Nano Research listed in Science Citation Index 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 6Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 7Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 8Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010 2Carl Zeiss Offers Online Promotions 2
... 8:30 am EDT to ... Discuss the Clinical Trial, Valley Cottage, ... LSE: XTL; TASE: XTL) today announced,the initiation of a Phase IIb ... - for the treatment of,diabetic neuropathic pain. Bicifadine is being ...
... Sept. 7 Chiltern, a leading global research,organization, ... Schulz,Chiltern,s Country Manager for the Czech Republic, received ... award ceremony was held in,London,s historic Gibson Hall. ... by a panel of judges who,reviewed his achievements ...
... October,18, 2007, Wyeth (NYSE: WYE ) will announce ... hold a one-hour conference call with,research analysts at 7:30 ... others may listen to the call live or on ... accessed by visiting our website,at http://www.wyeth.com and ...
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:3/21/2010)... March 21, 2010 A potential new energy source ... science is moving closer to acceptance by the mainstream ... one of the largest scientific sessions on the topic ... next two days in the Moscone Center during the ... , "Years ago, many scientists were afraid to speak ...
(Date:3/18/2010)... Boston, Mass. -- Hemangiomas -- strawberry-like birthmarks that commonly ... up to 10 percent cause tissue distortion or destruction ... 1960s, problematic hemangiomas have been treated with corticosteroids such ... effects, don,t always work, and their mechanism of action ...
(Date:3/18/2010)... WORCESTER, Mass. The Center for Wireless Information Network ... a three-year, $1.2 million award from the National Institute ... study of the propagation of radio waves around and ... of electrical and computer engineering and director of CWINS, ...
Breaking Biology News(10 mins):'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4Stem cells used to model infant birth defect 2Stem cells used to model infant birth defect 3WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3JNCI news brief 3A Surgeon training found effective in breast cancer sentinel lymph node trial 55206 1YORK Label Announces Continued Investment in the Company 55202 1YORK Label Announces Continued Investment in the Company 55202 2The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2
... because undifferentiated cells with features typical of stem cells ... brain, and muscles, scientists are beginning to assume that ... from the Max Planck Institute for Heart and Lung ... a study published in the journal Molecular and Cellular ...
... a plethora of dog genome-related materials are published, including a ... and a series of primary research articles in the journal ... publication by Nature of a high-quality draft sequence ... and the public with informative resources about canine genomics and ...
... and over during the bowl and NFL playoff seasons: a ... hitting the back of his head on the landing. , ... the skull? Researchers and doctors long have relied upon ... that infer ?rather loosely ?what happens to the brain during ...
Other Biology News:Forgotten by evolution? 2Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4New technique puts brain-imaging research on its head 2New technique puts brain-imaging research on its head 3
... integrated digital microscope and camera system that ... optical adjustment or software installation. Built on ... combines simplicity and advanced technology for users ... viewing of a macro image and a ...
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
... assay kit provides complete components including ... convenient detection of DNA fragmentation in ... incorporation of BrdU in the procedure ... digoxigenylated methods. Results can be analyzed ...
... amazing new range of ergonomic microscopes are ... a small footprint. The DM-BA200 comes packed ... and an exchangeable USB2.0 plug and play ... Achromat objectives mounted on a reversed quadruple ...
Biology Products: